Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

In propensity score-matched cohorts of 121,046 hospitalized patients, those with RA and T2D had an ILD prevalence of 2.25%, ...

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

As the name implies, cough is the signature symptom, and it can go on for weeks. Whooping cough can develop into a more ...

CDC data shows that whooping cough cases are rising in the U.S. Experts say routine immunization is the best way to prevent ...

Background: Children presenting with chronic cough are common to the primary care physicians, but data on the etiology are scant. Methods: We evaluated 40 children (age range, 5 to 12 years ...

Whooping cough is another word for pertussis, a highly contagious bacterial infection that causes intense coughing fits, according to the CDC. People who have whooping cough usually make a ...

Whooping cough cases have jumped sharply year over year but remain in line with pre-pandemic numbers, the Centers for Disease Control and Prevention announced Thursday. The CDC, which tracks ...

Mucociliary dysfunction, chronic infections with advancing immunosenescence and pulmonary emphysema as seen in COPD may be just as relevant to ACOS. Possible drug targets include receptors of the ...